Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 2/3 6Phase 4 5Phase 3 4Phase 1/2 3Phase 1 2Phase NA 1

Status

Unknown 6Completed 2

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 6

Conditions

Breast Neoplasms 33Carcinoma, Hepatocellular 27Neoplasms 19Colorectal Neoplasms 18Carcinoma, Non-Small-Cell Lung 16Stomach Neoplasms 15Leukemia, Myeloid, Acute 15Prostatic Neoplasms 12Lung Neoplasms 12Colonic Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Rectal Neoplasms 10Neoplasm Metastasis 8Leukemia 8Pancreatic Neoplasms 7NSCLC 6Multiple Myeloma 6Liver Neoplasms 6Esophageal Neoplasms 6Glioblastoma 5Small Cell Lung Carcinoma 4Recurrence 4Nasopharyngeal Carcinoma 4Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Head and Neck Neoplasms 4Gestational Trophoblastic Disease 4Esophageal Squamous Cell Carcinoma 4Cholangiocarcinoma 4Brain Neoplasms 4

Interventions

spartalizumab 1aflutinib 1Tyrosine Kinase Inhibitors 1Thalidomide 1Radiosurgery 1Pemetrexed 1Immune Checkpoint Inhibitors 1Gefitinib 1Drug Therapy 1Axitinib 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2/3 × Unknown × NSCLC × Clear all
NCT03256981 2023-12-26

HALT

Institute of Cancer Research, United Kingdom

Phase 2/3 Unknown
113 enrolled
Thoracic

NSCLC

NCT06020352 2023-08-31

The Efficacy and Safety of KN046 Combined With Axitinib

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2/3 Unknown
20 enrolled
Thoracic

NSCLC

NCT05605613 2022-11-09

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

The First Affiliated Hospital of Zhengzhou University

Phase 2/3 Unknown
150 enrolled
Thoracic

NSCLC

NCT05209256 2022-01-26

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

The First Affiliated Hospital of Henan University of Science and Technology

Phase 2/3 Unknown
90 enrolled
Thoracic

NSCLC

NCT04874844 2021-05-10

JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety

Beijing Dongfang Biotech Co., Ltd.

Phase 2/3 Unknown
420 enrolled
Thoracic

NSCLC

NCT02387086 2015-03-12

Gefitinib Combined With Thalidomide to Treat NSCLC

Shaanxi Provincial People's Hospital

Phase 2/3 Unknown
380 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡